International Assets Investment Management LLC Makes New Investment in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

International Assets Investment Management LLC acquired a new position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ) in the third quarter, according to the company in its most recent filing with the SEC. The firm acquired 60,161 shares of the specialty pharmaceutical company’s stock, valued at approximately $6,703,000. International Assets Investment Management LLC owned 0.10% of Jazz Pharmaceuticals at the end of the most recent quarter.

A number of other hedge funds also recently modified their holdings of the company. Capital World Investors acquired a new position in shares of Jazz Pharmaceuticals in the 1st quarter worth approximately $171,943,000. Swedbank AB acquired a new position in shares of Jazz Pharmaceuticals in the 2nd quarter worth approximately $106,936,000. Rubric Capital Management LP acquired a new position in shares of Jazz Pharmaceuticals in the 2nd quarter worth approximately $65,812,000. Pacer Advisors Inc. raised its holdings in shares of Jazz Pharmaceuticals by 40.7% in the 2nd quarter. Pacer Advisors Inc. now owns 1,820,913 shares of the specialty pharmaceutical company’s stock worth $194,346,000 after buying an additional 527,187 shares in the last quarter. Finally, Baupost Group LLC MA increased its holdings in Jazz Pharmaceuticals by 52.8% during the 2nd quarter. Baupost Group LLC MA now owns 1,274,248 shares of the specialty pharmaceutical company’s stock valued at $136,000,000 after purchasing an additional 440,552 shares in the last quarter. Institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Stock Down 2.8 %

NASDAQ:JAZZ opened at $110.03 on Friday. Jazz Pharmaceuticals plc has a 12-month low of $99.06 and a 12-month high of $134.48. The company has a quick ratio of 2.02, a current ratio of 2.37 and a debt-to-equity ratio of 1.36. The firm has a market capitalization of $6.79 billion, a P/E ratio of 18.91, a P/E/G ratio of 1.41 and a beta of 0.57. The stock’s fifty day simple moving average is $110.84 and its 200-day simple moving average is $109.56.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last posted its quarterly earnings results on Wednesday, July 31st. The specialty pharmaceutical company reported $4.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.80 by $0.87. Jazz Pharmaceuticals had a return on equity of 28.65% and a net margin of 10.10%. The business had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1 billion. Equities research analysts expect that Jazz Pharmaceuticals plc will post 16.06 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the company. Morgan Stanley dropped their price target on Jazz Pharmaceuticals from $160.00 to $150.00 and set an “equal weight” rating for the company in a report on Friday, July 12th. Royal Bank of Canada raised their price target on Jazz Pharmaceuticals from $175.00 to $179.00 and gave the company an “outperform” rating in a report on Wednesday, October 23rd. Needham & Company LLC reaffirmed a “buy” rating and set a $205.00 price target on shares of Jazz Pharmaceuticals in a report on Tuesday, September 10th. Wells Fargo & Company dropped their price target on Jazz Pharmaceuticals from $140.00 to $120.00 and set an “equal weight” rating for the company in a report on Thursday, August 1st. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $140.00 price target on shares of Jazz Pharmaceuticals in a report on Monday, September 9th. Three analysts have rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $173.43.

Insider Transactions at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, SVP Mary Elizabeth Henderson sold 1,410 shares of Jazz Pharmaceuticals stock in a transaction dated Friday, September 6th. The stock was sold at an average price of $108.30, for a total transaction of $152,703.00. Following the transaction, the senior vice president now directly owns 14,531 shares in the company, valued at approximately $1,573,707.30. The trade was a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. 4.20% of the stock is owned by corporate insiders.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.